ZVSA ZyVersa Therapeutics Inc
5,148
$4.49
$0.3728
(7.67%)
| Watchers | 5,148 |
| 52-Wk Low | $4.44 |
| 52-Wk High | $180.25 |
| Market Cap | $3.75M |
| Volume | 96,184.00 |
| 52-Wk High | $180.25 |
| 52-Wk Low | $4.44 |
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesGlobe Newswire • about 1 month ago
Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data...
Share to Feed
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA Get Free Report) saw a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 646,000 shares...
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical...
Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration...
According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world.ZyVersa is...
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA Get Free Report) was the target of a large growth in short interest in February. As of February 29th, there was short interest totalling 1,190,000...
ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2...
ZyVersa Therapeutics shares are trading higher by 126% Monday. The stock continues to be volatile after the company last week released a white paper.
read more...